Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.68 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.68 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.48 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4113120 | 1.00 | GPR84 (0.68) | GPR84FFAR1FFAR4MAPTLCK | |
| SCHEMBL4111726 | 1.00 | GPR84 (0.68) | GPR84FFAR1FFAR4MAPTLCK | |
| SCHEMBL27534006 | 1.00 | GPR84 (0.68) | GPR84FFAR1FFAR4MAPTLCK | |
| SCHEMBL6594188 | 0.90 | — | — | |
| Bicarbonate SCHEMBL8846757 | 0.84 | GPR84 (0.95) | GPR84FFAR1FFAR4MAPTLCK | |
| SCHEMBL11812812 | 0.82 | GPR84 (0.63) | GPR84FFAR1FFAR4MAPT | |
| SCHEMBL2709599 | 0.81 | GPR84 (1.00) | GPR84FFAR1FFAR4MAPTLCK | |
| SCHEMBL22842 | 0.81 | GPR84 (1.00) | GPR84FFAR1FFAR4MAPTLCK | |
| SCHEMBL4757199 | 0.81 | GPR84 (1.00) | GPR84FFAR1FFAR4MAPTLCK | |
| SCHEMBL524494 | 0.81 | GPR84 (1.00) | GPR84FFAR1FFAR4MAPTLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076136-A1 | THERAPEUTIC AGENT | ENOKI TATSUJI | 2009-03-19 | — | — | US | disclosed |
| US-20070060641-A1 | Therapeutic agent | TAKARA BIO INC. (JP) | 2007-03-15 | — | — | US | disclosed |
| EP-1627632-A1 | THERAPEUTIC AGENT | TAKARA BIO INC. (JP) | 2006-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076136-A1 | THERAPEUTIC AGENT | GPR119, IAPP, FABP4 | GPR84 564/4885FFAR1 124/4885FFAR4 138/4885 |
| US-20070060641-A1 | Therapeutic agent | GPR119, IAPP, FABP4 | GPR84 564/4885FFAR1 124/4885FFAR4 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.